Editorial: 21st century advances in type 1 diabetes research and immunotherapy

Bibliographic Details
Main Author: David Bleich
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1213417/full
_version_ 1797828878944698368
author David Bleich
author_facet David Bleich
author_sort David Bleich
collection DOAJ
first_indexed 2024-04-09T13:12:35Z
format Article
id doaj.art-9584278f2b414f23826dcd1f84fc56a6
institution Directory Open Access Journal
issn 1664-3224
language English
last_indexed 2024-04-09T13:12:35Z
publishDate 2023-05-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj.art-9584278f2b414f23826dcd1f84fc56a62023-05-12T06:36:39ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-05-011410.3389/fimmu.2023.12134171213417Editorial: 21st century advances in type 1 diabetes research and immunotherapyDavid Bleichhttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1213417/fulltype 1 diabetesT cellsimmunologymicrobiomeneoantigenGAD 65
spellingShingle David Bleich
Editorial: 21st century advances in type 1 diabetes research and immunotherapy
Frontiers in Immunology
type 1 diabetes
T cells
immunology
microbiome
neoantigen
GAD 65
title Editorial: 21st century advances in type 1 diabetes research and immunotherapy
title_full Editorial: 21st century advances in type 1 diabetes research and immunotherapy
title_fullStr Editorial: 21st century advances in type 1 diabetes research and immunotherapy
title_full_unstemmed Editorial: 21st century advances in type 1 diabetes research and immunotherapy
title_short Editorial: 21st century advances in type 1 diabetes research and immunotherapy
title_sort editorial 21st century advances in type 1 diabetes research and immunotherapy
topic type 1 diabetes
T cells
immunology
microbiome
neoantigen
GAD 65
url https://www.frontiersin.org/articles/10.3389/fimmu.2023.1213417/full
work_keys_str_mv AT davidbleich editorial21stcenturyadvancesintype1diabetesresearchandimmunotherapy